Mechanism of immunomodulatory drugs in multiple myeloma
| Authors | |
|---|---|
| Year of publication | 2012 |
| Type | Article in Periodical |
| Magazine / Source | Leukemia Research |
| MU Faculty or unit | |
| Citation | |
| Doi | http://dx.doi.org/10.1016/j.leukres.2012.05.010 |
| Field | Oncology and hematology |
| Keywords | Multiple myeloma; Treatment; Immunomodulatory drugs; Thalidomide; Lenalidomide; Pomalidomide |
| Attached files | |
| Description | Multiple myeloma is the second most common hematological cancer in the world. It is characterized by accumulation of malignant plasma cells in the bone marrow, osteolytic lesions and monoclonal immunoglobulins in blood/urine. With the introduction of immunomodulatory drugs into the treatment protocol, the outcome of multiple myeloma patients has dramatically improved with more than 30% of patients surviving for 10 years thus shifting multiple myeloma to a treatable condition. |
| Related projects: |
|